CCTG LY18-A, NCT04161248: Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma |
|
|
| Recruiting | 1 | 18 | Canada | Venetoclax, Rituximab Injection, Rituximab SC, Gemcitabine, Dexamethasone, Cisplatin, Glofitamab, Tafasitamab | Canadian Cancer Trials Group, Roche Pharma AG, AbbVie, Incyte Corporation | Lymphoma, B-Cell | 12/25 | 07/26 | | |